Clinical Trials Browser

Phase 1 × xentuzumab × Thoracic × Clear all

NCT02191891 2025-06-25

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

32 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung